FDA picks Wave's DMD program for innovative trial pilot

Wave Life Sciences Ltd. (NASDAQ:WVE) said FDA has selected a Phase II/III trial of its Duchenne muscular dystrophy candidate suvodirsen (WVE-210201) for the agency's pilot program on complex innovative trial designs. Wave expects to begin the global trial this year.

FDA launched the pilot in August to help individual companies overcome barriers to employing innovative trial protocols, and in the process create public case studies that can inform industry (see "FDA Pilot to Promote Clinical Trial Innovation")...